Introduction {#s1}
============

Life expectancy for people with Down syndrome (DS) has increased in Australia,[@R1] Japan[@R2] and other advanced countries. In Japan, improvements in early survival have been attributed to surgical intervention for congenital heart disease (CHD).[@R3] In Australia, in contrast to female longevity in the general population, males with DS were found to have significantly longer life expectancies, compared with their female counterparts.[@R4] The shorter life expectancy of these females may be attributed to their higher prevalence of CHD. This study aimed to clarify sex differences in the prevalence and severity of CHD among Japanese people with DS.

Methods {#s2}
=======

We used data from medical records from five hospitals in Tokyo and two questionnaires completed by parents of people with DS in Tokyo and Shizuoka prefectures ([online supplementary file 1](#SP1){ref-type="supplementary-material"}). People with DS were not directly involved in the design of this study. Small (diameter\<6 mm) fossa ovalis defects were excluded from the diagnosis of atrial septal defect (ASD). Arterial ducts closed before 1 month of age were excluded from the diagnosis of patent ductus arteriosus (PDA). Questionnaires were mailed to parents of people with DS; completing and returning the questionnaire was considered to indicate consent to participate. Statistical analyses were performed using SPSS V.21.
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Results {#s3}
=======

In total, there were 1310 subjects with DS (626 females and 684 males; sex ratio=1.09). The prevalence of CHD was significantly higher among females (354, 57%) than among males (338, 49%; χ^2^ test: p=0.010). Moreover, significantly more females (199, 32%) than males (175, 26%) underwent cardiac surgery (χ^2^ test: p=0.018; [table 1](#T1){ref-type="table"}). The main CHD lesions (in order of prevalence) were ventricular septal defect (VSD), ASD, atrio-VSD (AVSD), PDA and tetralogy of Fallot (TOF; [table 2](#T2){ref-type="table"}). The prevalence of CHD with PDA was significantly higher in females (115, 18%) than in males (87, 13%; p=0.005), whereas the prevalence of CHD without PDA was almost equal in females (239, 38%) and males (251, 37%.) Among subjects born before 1979 (female: 34, 43.6%; male: 10, 18.5%), in the 1980s (female: 63, 51.2%; male: 46, 37.7%) or in the 1990s (female: 74, 59.7%; male: 85, 47.5%), more females than males had CHD, but we found no significant sex difference in CHD prevalence for subjects born in 2000 or later (female: 183, 60.8%; male: 196, 59.8%).

###### 

Congenital heart disease (CHD) and operations among people with Down syndrome by sex

  ----------------------------------------
  Sex      CHD (+)   CHD\   Total   
                     (−)            
  -------- --------- ------ ------- ------
  Female   199       155    272     626

  32%      25%       43%    100%    

  Male     175       163    346     684

  26%      24%       51%    100%    

  Total    374       318    618     1310

  29%      24%       47%    100%    
  ----------------------------------------

χ^2^=8.05, df=2, p=0.018.

Odds: female versus male with CHD (95% CI) 1.33 (1.07 to 1.66).

Odds: female versus male with CHD operation (95% CI) 1.36 (1.07 to 1.72).

###### 

Main congenital heart disease (CHD) lesion among people with Down syndrome by sex

  --------------------------------------------------------
  Main lesion\   Sex   Total                       
  of CHD                                           
  -------------- ----- ------- ----- ------- ----- -------
  VSD            142   40.1    131   38.8    273   39.5

  ASD            75    21.2    70    20.7    145   21.0

  AVSD           55    15.5    47    13.9    102   14.7

  PDA            48    13.6    40    11.8    88    12.7

  TOF            23    6.5     30    8.9     53    7.7

  PS             1     0.3     5     1.5     6     0.9

  DORV                 0.0     3     0.9     3     0.4

  Ebstein        1     0.3     1     0.3     2     0.3

  AR             1     0.3           0.0     1     0.1

  CoA                  0.0     1     0.3     1     0.1

  MR             1     0.3           0.0     1     0.1

  TA                   0.0     1     0.3     1     0.1

  TR                   0.0     1     0.3     1     0.1

  Unknown        7     2.0     8     2.4     15    2.1

  Total          354   100.0   338   100.0   692   100.0
  --------------------------------------------------------

AR, aortic regurgitation;ASD, atrial septal defect;AVSD, atrioventricular septal defect;CoA, coarctation of aorta;DORV, double outlet right ventricle;Ebstein, Ebstein's anomaly;MR, mitral regurgitation;PDA, patent ductus arteriosus;PS, pulmonary stenosis;TA, tricuspid atresia;TOF, tetralogy of Fallot;TR, tricuspid regurgitation; VSD, ventricular septal defect.

Discussion {#s4}
==========

In our study, females with DS had a significantly higher prevalence of CHD than did males with DS, as has previously been reported in the USA[@R5] and Europe.[@R6] Higher prevalence and greater severity of CHD in females may contribute to poor prognoses. We found that the most common cardiac anomalies (main lesions) were VSD, ASD, AVSD, PDA and TOF, which together accounted for 95.5% of all CHD cases. Likewise, a European network of population-based registers for the epidemiological surveillance of congenital anomalies study[@R6] found that these five anomalies accounted for more than 99% of cardiac anomaly cases in people with DS. Among people with DS born before 1979, in the1980s or 1990s, we found that significantly more female than male subjects had CHD, but we found no significant sex difference for subjects born in 2000 or later. Many factors seem to have contributed to this change, including the improvement of diagnostic techniques, such as echocardiographic examination, and improvements in heart surgery. This shift may be attributed to a great increase in the diagnosis of less severe CHD for both sexes.
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